Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2021-01-19 Earnings Release
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 96% confidence The document is dated January 19, 2021, and explicitly announces the company's revenue (chiffre d'affaires) for the full year 2020, detailing key financial figures, comparisons to the previous year, and outlining the strategy for 2021. This structure—reporting on a completed fiscal year's performance with detailed financial tables and management commentary—is characteristic of an Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR). Since it covers the full year (2020) and includes detailed financial breakdowns, it strongly suggests an annual filing. However, the text is presented as a press release announcing the results, not the formal 10-K filing itself. In the context of the provided definitions, a document that releases the initial key highlights of periodical financial results is an Earnings Release (ER). While this document is quite detailed, it functions as the primary announcement of the annual results, often preceding the full 10-K filing. Given the focus on 'chiffre d'affaires pour l'année 2020' and the strategic outlook, it fits best as an Earnings Release (ER) or potentially a Management Discussion & Analysis (MDA) if it were more focused on commentary than raw results. Since it leads with the revenue announcement and includes tables summarizing the annual performance, ER is the most appropriate classification for this type of preliminary announcement. FY 2020
2021-01-19 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR THERACLION AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL" (Semi-annual statement of the liquidity contract entered into by Theraclion with Crédit Industriel et Commercial). It details the status of a liquidity contract (market making/stabilization agreement) as of December 31, 2020, covering the second half of 2020. This type of disclosure, focusing on transactions related to share liquidity management, is a specific regulatory requirement, often related to insider dealings or market operations, but it is not a standard periodic financial report (10-K, IR, ER, MRQ). It reports on transactions by an agent on behalf of the company, which is closely related to insider/director dealings or specific capital structure management. Given the options, this document reports on transactions involving the company's own shares managed under a specific agreement, which aligns most closely with 'Transaction in Own Shares' (POS) or potentially 'Director's Dealing' (DIRS) if the agent is considered an insider proxy, or 'Regulatory Filings' (RNS) as a catch-all for specific market disclosures. Since it details the activity of a liquidity contract (share repurchase/stabilization activity), POS is the most specific fit among the choices for reporting on transactions in the company's own stock, even if executed by a third party under mandate. It is a detailed report, not just an announcement of a report (ruling out RPA/RNS based on length and content).
2021-01-15 French
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is a press release dated December 17, 2020, announcing that the company, Theraclion, has successfully raised €3.0 million from investors (subscribing the second tranche of an investment contract) and secured €1.5 million in PGE loans. It details the use of these funds for commercial rollout and further development. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER) focusing on operational results, or a general regulatory filing (RNS), as it is highly specific to a financing event.
2020-12-17 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is a press release dated December 17, 2020, announcing that Theraclion has secured €3.0 million from investors (Tranche 2 of an investment agreement) and an additional €1.5 million in state-guaranteed loans (PGEs). The content focuses on financing activities, capital structure updates, and the use of funds for technological advancement and commercial deployment. This directly aligns with the definition of 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT).
2020-12-17 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a short press release dated November 13, 2020, announcing that the company Theraclion confirms its eligibility for the PEA-PME investment scheme in France. This type of announcement, which details compliance with a specific regulatory or financial status (like tax eligibility or listing requirements) and is not a standard periodic report (10-K, IR, ER), nor a management change (MANG) or dividend notice (DIV), fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'Capital/Financing Update' (CAP) due to its impact on investment vehicles. Given the focus is on regulatory eligibility for an investment plan (PEA-PME), RNS is the most appropriate fallback for non-standard regulatory news. The document length is short (2786 chars), but it is a substantive announcement, not just a notice of another report's publication, so RPA is less suitable than RNS for this specific regulatory status update.
2020-11-13 French
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de rachat
Transaction in Own Shares Classification · 100% confidence The document is titled "Descriptif du programme de rachat d'actions 2020" (Description of the 2020 share buyback program). It details the objectives, modalities, maximum number of shares, price, and duration of a share repurchase program authorized by the General Meeting. This content directly relates to the company acquiring its own shares, which corresponds precisely to the definition of 'Transaction in Own Shares' (POS). It is not a general financing update (CAP) but a specific execution plan for repurchases.
2020-11-13 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.